Follow

Implantica presents the first quarter 2021 on May 12 at 15:00 CEST

05 May 2021 - 08:00

Implantica AG (publ) invites investors to a presentation of the first quarter 2021 at 15:00 CEST on May 12. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.

The presentation will be in English via an audiocast with teleconference:

Conference call dial-in:

  • Sweden: +46 85-055 83 57
  • United Kingdom: +44 3333 009269
  • United States: +1-833-526-8382

Webcast:

Speakers:

  • CEO Peter Forsell
  • CFO Andreas Öhrnberg
  • VP Operations & IR Nicole Pehrsson
 

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]

The information was sent for publication, through the agency of the contact person set out above, on May 5, 2021 at 8:00 CEST.

 

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

Provided by: Cision
Nasdaq First North GM (Sweden)
Implantica AG
Implantica AG is a medtech group providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More